Business Context and Reporting Period
Company: Niagen Bioscience, Inc. (NAGE)
Filing Type: Form 8-K (Current Report)
Date of Report: October 6, 2025
Reporting Period: Full year ending December 31, 2025
The Company filed this report to disclose a Regulation FD announcement regarding an update to its financial outlook for the fiscal year 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves solely as a notification of an updated outlook rather than a detailed financial statement.
Material Changes
- Outlook Revision: The Company announced an increase in its financial outlook for the full year ending December 31, 2025.
- Source of Data: Specific details regarding the magnitude of the increase are contained in the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Guidance, Outlook, and Management Commentary
Management has issued a positive revision to its full-year 2025 financial guidance. The filing explicitly states that the Company has increased its financial outlook. No specific risks, contingencies, or unusual items are detailed within the body of this 8-K filing; the document directs readers to the attached press release for further information.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated October 6, 2025) for specific numerical targets regarding the increased outlook.
- Verify the specific metrics being revised (e.g., revenue, EPS, or cash flow) as the 8-K text does not specify which line items were adjusted.
- Confirm the trading status of Common Stock (NAGE) on The Nasdaq Capital Market.